Loading clinical trials...
Loading clinical trials...
Evaluation of Safety of Activated Recombinant FVII as an Add-On Therapy in Spinal Surgery
Conditions
Interventions
eptacog alfa (activated)
Locations
14
United States
Novo Nordisk Investigational Site
Sacramento, California, United States
Novo Nordisk Investigational Site
San Francisco, California, United States
Novo Nordisk Investigational Site
Washington D.C., District of Columbia, United States
Novo Nordisk Investigational Site
Miami, Florida, United States
Novo Nordisk Investigational Site
Atlanta, Georgia, United States
Novo Nordisk Investigational Site
Chicago, Illinois, United States
Start Date
July 1, 2004
Primary Completion Date
February 1, 2006
Completion Date
February 1, 2006
Last Updated
January 13, 2017
NCT06282770
NCT06820190
NCT06042699
NCT06233617
NCT04439032
NCT07378735
Lead Sponsor
Novo Nordisk A/S
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions